GT Biopharma, Inc. (GTBP)
6.68
+0.72
(+12.08%)
USD |
NASDAQ |
Oct 09, 16:00
6.79
+0.11
(+1.65%)
After-Hours: 20:00
GT Biopharma EPS Diluted (Quarterly) : -2.957 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.957 |
| March 31, 2026 | -2.781 |
| December 31, 2025 | -110.33 |
| September 30, 2025 | 25.99 |
| June 30, 2025 | -272.88 |
| March 31, 2025 | -8.272 |
| December 31, 2024 | -42.24 |
| September 30, 2024 | -38.17 |
| June 30, 2024 | -54.18 |
| March 31, 2024 | -41.03 |
| December 31, 2023 | -53.63 |
| September 30, 2023 | -44.18 |
| June 30, 2023 | -37.19 |
| March 31, 2023 | -4.358 |
| December 31, 2022 | -127.99 |
| September 30, 2022 | -164.46 |
| June 30, 2022 | -71.53 |
| March 31, 2022 | -125.60 |
| December 31, 2021 | -421.58 |
| September 30, 2021 | -130.33 |
| June 30, 2021 | -108.77 |
| March 31, 2021 | -1370.56 |
| December 31, 2020 | -2146.34 |
| September 30, 2020 | -477.87 |
| June 30, 2020 | -3089.45 |
| Date | Value |
|---|---|
| March 31, 2020 | -310.72 |
| December 31, 2019 | -268.52 |
| September 30, 2019 | -6478.02 |
| June 30, 2019 | -684.93 |
| March 31, 2019 | -1125.44 |
| December 31, 2018 | -1065.01 |
| September 30, 2018 | -59939.41 |
| June 30, 2018 | -2295.00 |
| March 31, 2018 | -2550.00 |
| December 31, 2017 | -1533.06 |
| September 30, 2017 | -103912.0 |
| June 30, 2017 | -19.66M |
| March 31, 2017 | -100.83M |
| December 31, 2016 | -346086.0 |
| September 30, 2016 | -497250.0 |
| June 30, 2016 | 229500.0 |
| March 31, 2016 | 3.213M |
| December 31, 2015 | -34.27M |
| September 30, 2015 | -2.697M |
| June 30, 2015 | 19.13M |
| March 31, 2015 | -28.69M |
| December 31, 2014 | -30.11M |
| September 30, 2014 | -6.837M |
| June 30, 2014 | -439875.0 |
| March 31, 2014 | -621562.5 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -4.518M |
| Total Expenses (Quarterly) | 4.518M |
| Enterprise Value | 6.883M |
| Earnings Yield | -1.35K% |
| Normalized Earnings Yield | -2579.14 |